Nucleix, a leader in liquid biopsy technology focused on early cancer detection, announced that European Urology Oncology published a study highlighting the benefits of using Bladder EpiCheck alongside standard white light cystoscopy for monitoring non-muscle invasive bladder cancer in patients at high risk for recurrence. The study evaluated 231 patients with high-grade NMIBC over a median follow-up of 16 months, covering 316 surveillance visits that included both Bladder EpiCheck and standard white light cystoscopy. The findings revealed that Bladder EpiCheck detected 92 percent of recurrence events, including 90 percent of high-grade NMIBC or muscle-invasive cases and all low-grade NMIBC cases, compared to 62 percent, 63 percent, and 57 percent detection rates for white light cystoscopy. Notably, for carcinoma in situ cases, Bladder EpiCheck identified 92 percent while cystoscopy detected only 38 percent, demonstrating its ability to uncover aggressive tumors that could otherwise be missed.

Health Technology Insights: Link Cell Therapies Launches to Advance CAR-T Cancer Treatments

Professor Param Mariappan, Consultant Urological Surgeon at Western General Hospital, Edinburgh, and a member of the European NMIBC and MIBC Guidelines Committees, explained the significance of these results. He stated that carcinoma in situ is among the most aggressive forms of bladder cancer and can progress to muscle-invasive stages in up to 60 percent of untreated cases. Missing early-stage CIS often results in cystectomy and dramatically lowers five-year survival rates. This study shows that Bladder EpiCheck can detect tumors at an earlier stage, allowing for timely intervention, potentially preventing bladder removal, and improving patient outcomes.

Health Technology Insights: Dilon Technologies Gets FDA Approval for MarginProbe 2 Launch

Chris Hibberd, Chief Executive Officer of Nucleix, expressed enthusiasm about the study, highlighting that Bladder EpiCheck has the potential to significantly enhance the management and care of patients with NMIBC. The study underscores the value of integrating advanced molecular diagnostics with conventional monitoring methods to improve early detection and overall patient prognosis.

Health Technology Insights: Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com